In the summer of 2004, Rafaat founded Lifescience Dynamics. He had a vision of what would make an effective global decision support service, dedicated exclusively to pharmaceutical and biotechnology industries. It would have to be the best in class market research, competitive intelligence and market access, combined with first-rate people and a business model that met their clients’ global insight and foresight requirements. He wanted to deliver a unique service model that hadn’t been available to the market previously, giving pharmaceutical companies a new and interesting way to manage their market, competitors and payer requirements.

Prior to founding Lifescience Dynamics, Rafaat was Vice President of a London-based consulting practice where he was responsible for numerous international projects for top 10 pharmaceutical companies, focusing on all aspects of the clinical development and commercialisation environments at US, European and global levels. He has advanced knowledge of competitive intelligence, qualitative and quantitative market research techniques, market access, pricing and reimbursements, and he gets personally involved in all aspects of the client engagement process as well as execution of studies. He has also previously worked for Eli Lilly & Company, Pepsi-Cola and McDonald's in a management training programme.

Rafaat has a truly international background. He was born in India, brought up in Oman/UAE, gained a business degree in the USA and an MBA from Manchester Business School in the UK. As well as the UK, he has worked in the USA, India, Abu Dhabi and Dubai. He belongs to a large, traditional close-knit Indian family with strong family ethics and values of honesty and hard work. He says: "I was told from childhood and have always believed that it's not just what you do but how you do it that's important."

Political scientist with advocacy and project management experience.

Market Acces and Public Affairs Executive with experience at national, european and global level and deep konwlegde of National and Regional Italian Health System and tender managment process. Proven track record of positive reimbursement processes and launch. Strong experience in market access plan definition and implementation both at regional and national level with good attitude to relationship and partnership with institutional stakeholders. Experience in product launch and in managment of in market portfolio product, price and reimbursement processes. Ideation of heath economics projects on support of reimbursement.
Coordination in P&R dossier preparation and reimbursement process.

Henriette Burghoorn is an experienced Associate Director of Market Access at Gilead Sciences, with a strong track record in the biotechnology industry. She has extensive expertise in reimbursement strategies across a broad range of therapeutic areas, including liver disease, HIV, oncology, hematology, cardiovascular, and diabetes indications. Henriette is known for her strategic insight and dedication to improving patient access to innovative treatments.

The Pop in Your Job
My passion in my work is on improving patients’ lives and making access to innovative medicins available for those patients in need. In the process of gaining access, I love transforming complex processes into intelligent, solutions that truly make an impact.

Saša Perović has been Market Access Manager for South East Europe at Hemofarm A.D. since 2015. Prior to joining Hemofarm, he served as Market Access Manager for Serbia and Montenegro at Bayer for nearly four years. Earlier in his career, he spent almost a decade as Executive Director of the National Health Insurance Fund of Serbia.

Lifescience Dynamics works across five practice areas: Market Research, Competitive Intelligence, and Market Access, Strategic Advisory and Real-World Evidence. The company’s success is attributed to its multinational team who work in a collaborative and nurturing environment, where they can develop their skills and advance their careers. Founded in 2004, Lifescience Dynamics has its headquarters in London and an office in Toronto, as well as virtual offices in Boston, New York, San Francisco and Vancouver.

For 15 years, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology. EUCOPE’s members – who represent over 2600+ innovative companies directly or via associations – are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent. Based in Brussels, Belgium, EUCOPE takes pride in providing expert insights into EU policies and legislation as well as market access, aiding our members in navigating the complex world of health technologies in Europe. EUCOPE’s network and trusted relationships with established stakeholders at the EU and national levels help our members connect and share experiences with the European Commission, the European Parliament, Member States’ representatives, patient organisations, healthcare professionals and payers, academics, and other industry associations. Our commitment is to lead and engage in partnerships spanning across the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve, and healthcare systems overall. www.eucope.org

At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas of oncology, nephrology and central nervous system (CNS) across Europe and the Middle East.

At Gilead, we strive to create a healthier world for all people. From our pioneering virology medicines to our growing impact in hematology and oncology, we deliver innovative therapies that offer hope to those impacted by disease. With more than 18,000 employees, we invest in world-class science and are pursuing innovation across our therapeutic areas of virology, oncology and inflammation.

Founded in 1960, Hemofarm A.D. is currently the leading generic pharmaceutical company in Serbia and in the region. Manufacturing high quality, effective, safe and affordable pharmaceutical products is the core activity of the company. Since 2006, Hemofarm has been a part of the German STADA Group, one of the largest generic pharmaceutical companies in the world. Hemofarm is the leader on the pharmaceutical market of Serbia. Taking up over 70% of the total exports of pharmaceutical products, the Vršac-based company is at the same time the largest Serbian exporter of drugs. Hemofarm manufactures about 6.6 billion tablets and capsules annually. It operates on four continents and it has a team of over 3,600 employees. In addition to being present on 34 markets around the World, Hemofarm is among the largest pharmaceutical manufacturers in this region.